IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy

Reuters03-16

IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy

IceCure released a corporate presentation outlining its ProSense cryoablation system and its U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy. The company said ProSense is the only minimally invasive cryoablation device with U.S. labeling for breast cancer and cited a total addressable market of USD 1.2 billion. IceCure reported regulatory approvals in 27 countries and said it has 64 full-time employees. It also described the ICE3 study, which enrolled 194 patients across 19 U.S. sites to evaluate cryoablation without lumpectomy. IceCure listed CEO Eyal Shamir and COO Shay Levav among its leadership team.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on March 15, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619100485?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619100485","market":"fut","top_or_hot":-1,"title":"IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IceCure released a corporate presentation outlining its ProSense cryoablation system and its U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy. The company said ProSense is the only minimally invasive cryoablation device with U.S. labeling for breast cancer and cited a total addressable market of USD 1.2 billion. IceCure reported regulatory approvals in 27 countries and said it has 64 full-time employees. It also described the ICE3 study, which enrolled 194 patients across 19 U.S. sites to evaluate cryoablation without lumpectomy. IceCure listed CEO Eyal Shamir and COO Shay Levav among its leadership team.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> published the original content used to generate this news brief on March 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-16 05:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IceCure released a corporate presentation outlining its ProSense cryoablation system and its U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy. The company said ProSense is the only minimally invasive cryoablation device with U.S. labeling for breast cancer and cited a total addressable market of USD 1.2 billion. IceCure reported regulatory approvals in 27 countries and said it has 64 full-time employees. It also described the ICE3 study, which enrolled 194 patients across 19 U.S. sites to evaluate cryoablation without lumpectomy. IceCure listed CEO Eyal Shamir and COO Shay Levav among its leadership team.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> published the original content used to generate this news brief on March 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nNDL174slP:1","article_id":"2619100485","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619100485","pubTimestamp":1773611110,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy. IceCure released a corporate presentation outlining its ProSense cryoablation system and its U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy. The company said ProSense is the only minimally invasive cryoablation device with U.S. labeling for breast cancer and cited a total addressable market of USD 1.2 billion. IceCure reported regulatory approvals in 27 countries and said it has 64 full-time employees. It also described the ICE3 study, which enrolled 194 patients across 19 U.S. sites to evaluate cryoablation without lumpectomy. IceCure listed CEO Eyal Shamir and COO Shay Levav among its leadership team.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ICCM":"IceCure Medical Ltd."},"translate_title":"IceCure Medical发布ProSense冷冻消融演示文稿，介绍内分泌疗法局部治疗低风险乳腺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":0.9},"content_text":"IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy\n    \n\n        IceCure released a corporate presentation outlining its ProSense cryoablation system and its U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy. The company said ProSense is the only minimally invasive cryoablation device with U.S. labeling for breast cancer and cited a total addressable market of USD 1.2 billion. IceCure reported regulatory approvals in 27 countries and said it has 64 full-time employees. It also described the ICE3 study, which enrolled 194 patients across 19 U.S. sites to evaluate cryoablation without lumpectomy. IceCure listed CEO Eyal Shamir and COO Shay Levav among its leadership team.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on March 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619100485","isCrawlerRequest":true}